Value and Access:
Health Economics and Outcomes Research (HEOR)
A dedicated team of subject-matter experts to build you the evidence you need.
Value and Access:
A dedicated team of subject-matter experts to build you the evidence you need.
In today’s competitive markets, the challenge is not only to articulate and quantify the value of your product but also to differentiate it to ensure a successful market access and reimbursement strategy.
Trinity’s Evidence and Outcomes solution, our Health Economics and Outcomes Research (HEOR) team, is purpose-built to strategically plan, execute, and deploy evidence to inform the product’s value strategy in the marketplace. Leveraging best-in-class, scientifically driven, publication-quality primary and secondary research methods, we help our clients demonstrate the holistic value of their assets across the product lifecycle. We proactively guide the development of publication-grade evidence to cover a broad range of communication needs, including driving disease-state awareness, increasing product awareness, identifying keys to successful adoption, and utilization. We work in partnership with our client partners to identify and overcome potential roadblocks, to strategically plan for market access challenges, and to create evidence to support their strategic pricing goals.
Trinity offers a complete suite of HEOR services, from strategy development (think: Evidence Generation Planning, Analog Assessments, KOL/HCP/Patient Engagement and Payer/HTA Strategy) to specific tactics (think: field tool development and deployment, HECON calculators and models), and all the evidence generation techniques (think: physician/patient surveys, RWE/Claims analyses). We apply a strategic lens, often incorporating multiple methodologies and cutting-edge services such as Discrete Choice Exercises (DCEs) to help our clients differentiate the value of their product vs. the competition. We work with our customers across all phases of a product’s lifecycle, from early clinical development all the way to launch and post-launch.
Our dedicated HEOR team is globally recognized for its expertise and has 60+ years of combined HEOR experience (85+ years of life sciences consulting experience). The team is led by an economist who presents annually at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and who has authored numerous white papers and peer-reviewed journal articles. She is supported by two Managing Directors, also leaders in the Evidence Generation/HEOR space, who also bring deep expertise in the sphere of HEOR/Evidence Generation/Scientific Dissemination.
Trinity’s HEOR team features advanced degrees including multiple PhD-level experts and has conducted ~70 HEOR projects in 2018-2019, and about that many in 2020 alone — a tremendous trajectory of growth. We consistently deliver high-quality insights and products to meet internal and external stakeholder needs. No wonder our repeat project rate with existing clients is >80%: 84% of our client partners come back to us for the next project, and 56% of our clients work with us on three or more projects.
PhDs, MBAs, MPHs, PharmD
The HEOR team offers end-to-end, full-service support: evidence strategy and planning, execution of publication-grade studies, and pull-through to scientific dissemination:
We help customers effectively navigate critical contemporary challenges with fit-for-purpose services including value quantification, strategic planning for differentiation and access, and deploying HEOR evidence-generation methodologies to maximize their product’s value story.
Developing the product value story begins with a strategic plan and tactical roadmap that lays out each step of evidence generation. Our roadmaps include value modeling, strategically incorporating Voice of Customer (VOC) research, leveraging real-world data and evidence (RWD/E) and scientifically communicating the product’s value in industry, clinical and payer forums, both in the US and around the globe.
Trinity integrates a multi-disciplinary suite of capabilities including secondary research (peer-reviewed literature searching/synthesis, real-world evidence/claims/Big Data) and both qualitative and quantitative primary research with physicians, payers, patients and caregivers. We analyze this data with our dedicated team of biostatisticians using advanced techniques. We conduct Medical Chart Audits when we need to capture not just what the care paradigm is but also physician rationale around the why and quantify the perceived unmet needs. In cases in which the holistic burden of illness is less defined/understood we employ a range of techniques to quantify the burden on not only patients but in some instances on their caregivers and families. We apply statistical techniques such as Discrete Choice Exercises/Trade-off Studies to quantify Physician/Patient Preferences and to differentiate our client’s products from the competition.
Develop a compelling and holistic value proposition (clinical, economic, and humanistic) and create strategic Evidence Generation Plans (EGPs/Roadmaps) to identify must-have evidence, publications, and the cadence for their creation
Conduct HCP/Patient/CG surveys to quantify Burden of Illness, treatment experiences and capture PROs, capture the holistic patient journey and identify unmet needs/gaps, and conduct trade-off studies/discrete-choice exercises to establish real-world treatment preferences
Conduct robust TLRs and PRISMA-grade SLRs to evaluate current treatment effectiveness, safety, and unmet needs to characterize the disease and conduct network meta analysis (NMA) for indirect comparisons across treatments
Quantify epi/incidence/prevalence, treatment patterns, treatment effectiveness; identify unmet needs/gaps in care paradigm, quantify cost of care and Tx use patterns including discontinuation/adherence, and understand the whys behind Rx decisions, capturing physician rationale
Generate HECON models and field tools to communicate cost of care, cost savings/budget impact to effectively communicate the product’s value proposition and develop strategic Value Dossiers and Value Presentations to communicate the product’s holistic value story
Create/enable scientific dissemination and develop stakeholder-targeted scientific publications, including Abstracts/Posters/Podium Presentations for industry conferences and manuscripts for clinical and/or economic journals
Below we describe just a couple of our Pillar Projects:
Evidence Generation Plans help customers meet the evidentiary needs of the product, differentiate it from currently available treatments and communicate its value proposition. Trinity is particularly effective at identifying “Must Have” evidence by geography and stakeholder type and supporting organizational alignment through creative and high-impact workshops, to create an actionable and well-resourced plan.
We convene discussions with both external and internal stakeholders to create a detailed evidence generation plan that includes study type (the majority of which Trinity has the capability to execute internally), timing, and alignment with internal cross-functional stage gates. We deliver the plan to customers through a dynamic, cross-functional workshop that aligns organizations around priorities and resources and serves as a compelling call to action.
Trinity’s Burden of Illness projects support disease awareness efforts and act as foundational information for both medical and commercial teams. Our methodologies leverage Big Data to generate publication-quality insights on resource utilization, cost, adherence, incidence, etc. We utilize our primary market research expertise to conduct research with patients and caregivers to paint a full picture of the disease, its clinical symptomology and its impact on social, mental and emotional wellness, as well as the impact on families (including parents and siblings). Establishing the burden of an illness serves as a strategic foundation to drive downstream product strategy—from an HEOR and commercial lens. Burden of Illness projects inform unmet needs in the current care paradigm and help pave the way for the new product’s value proposition.
Trinity’s Medical Chart Audits capture the real-world treatment paradigm from diagnosis, treatment and management patterns, and the resulting outcomes for patients. In short, our chart studies shine a light on today’s approach to patient care, as practiced in the real-world setting. They are designed to not only quantify line of therapy use and key outcomes metrics but also to address the why behind physician treatment decisions. The rationale behind physician treatment choices is key so we can quantify where current therapies are performing adequately and delivering good outcomes vs. where there are unmet needs and gaps in treatment. Our publication-grade Chart Audit studies have helped clients across a broad spectrum – from demonstrating unmet needs in the current SOC and paving the way for product launch to quantifying the relative outcomes benefits of a therapy vs. other treatments.
Additional projects include Systematic and Targeted Literature Reviews, Network Meta-Analysis, Value Dossier Development, Budget Impact Models, Cost-Effectiveness Analysis (CEA), and Claims/RWE projects to inform disease epidemiology, cost of care, and comparative effectiveness.
Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR
The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. To understand the implications of this growth, the Trinity Life Sciences Evidence Strategy team […]
How to Develop Strong Evidence to Enable Optimal Access Recording
Communicating a compelling value story to clinicians and payers is key to launching a product successfully and optimizing value throughout the product lifecycle. But how exactly does one generate evidence that will educate stakeholders on the disease state, shape the future market and support your value narrative? What are the ‘nuts and bolts’ of designing […]
Trinity Attends AMCP NEXUS
Join Trinity at AMCP NEXUS where we will share our integrated, evidence-based approach that helps clients make important decisions at the brand, business, and corporate levels including: corporate growth strategy: buy, build, or partner; business-unit and therapeutic-area assessments; identification of new business opportunities; resource allocation and investment decision support; In-depth market and competitive intelligence; development […]
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.